In the positive controls, doxorubicin hydrochloride enriched the genes involved in the Cell cycle, p53 signaling pathway, and multiple cancer pathways, including breast cancer, non-small cell lung cancer, small cell lung cancer, bladder, gastric, pancreatic, and prostate cancer. The gene discussed is TP53; the disease is breast carcinoma.